

**CURRICULUM VITAE**  
**Dr CHIANG, Chi Leung**

**Medical Professional Qualifications & Education**

Primary Degree

MBChB, Chinese University of Hong Kong (2004)

Postgraduate Degrees

Royal College of Radiologists – FRCR (UK) (2010)

Postgraduate Diploma of Epidemiology and Biostatistics, Chinese University of Hong Kong (2012)

Hong Kong College of Radiologists – FHKCR (HK) (2013)

Hong Kong Academy of Medicine (Radiology) – FHKAM (HK) (2013)

Hong Kong College of Radiologists – Palliative Medicine Sub-specialty Fellow (HK) (2016)

Postgraduate Training in Overseas Centres

John Hopkins Hospital, United States (2013)

Princess Margaret Hospital, Canada (2013)

Jewish General Hospital, Canada (2015)

**Academic Appointments**

Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, University of Hong Kong  
Clinical Assistant Professor (Since 2017)

**Clinical Appointments**

Department of Clinical Oncology, Tuen Mun Hospital

Resident (2005-2013)

Resident Specialist (2013-2016)

Honorary Resident Specialist (Since 2017)

Department of Clinical Oncology, Queen Mary Hospital

Honorary Resident (Since 2017)

The University of Hong Kong – Shenzhen Hospital

Consultant, Clinic Oncology Centre (Since Jan-2017)

Deputy COS, Clinical Oncology Centre (Since Oct-2017)

Gleneagles Hong Kong Hospital

Specialist in Clinical Oncology (Since 2017)

### Research Interests

- 1 Personalized approach in treatment of hepato-biliary-pancreatic, colorectal, and hepato-biliary-pancreatic cancer
- 2 Clinical application of stereotactic body radiotherapy (SBRT) in liver and pancreatic cancer
- 3 Clinical application of brachytherapy in rectal cancer

### Publications

#### Book Chapters

1. **CL Chiang**, SH Lo, A Agarwal. Prognostic Factors For Survival Prediction in Advanced Cancer patients And Development of a Simple Survival Prediction Tool for Application in A Community Palliative Care Setting. In Palliative Care: Oncology Experience From Hong Kong. Louisa C Lui, Kam-Hung Wong, Rebecca Yeung and Joav Merrick (Eds). Nova Science 2017

#### International Journal: Original Articles & Review Article

1. CHM Ho, **CL Chiang**, (co-first and corresponding author), FAS Lee, et al. Comparison of platelet-albumin-bilirubin (PALBI), albumin-bilirubin (ALBI), and child-pugh (CP) score for predicting of survival in advanced HCC patients receiving radiotherapy (RT). Oncotarget 2018 (in the press) (Impact factor: 5.168)
2. **CL Chiang**, SH Lo, A Agarwal et al. Prognostic factors for survival prediction in advanced cancer patients and development of a simple survival prediction tool for application in a community palliative care setting: A retrospective cohort study. Journal of Pain Management 2018 Volume 11 Issue 1
3. **CL Chiang** (first and corresponding author), TH So, ZJ Chen, VH Lee, AW Lee. Pursuit of Excellence in the Management of Nasopharyngeal Carcinoma (NPC). International Journal of Head and Neck Science 1(4): 199-211, 2017
4. SF Lee, **CL Chiang** (corresponding author), FAS Lee, YW Wong, CM Poon, FCS Wong, SY Tung. Neo-adjuvant Chemoradiation for Locally Advanced Rectal Cancer: Retrospective Analysis of 123 Chinese Patients. J Formos Med Assoc. 2017 Nov 1. (Impact factor: 1.969)
5. KH Chan, **CL Chiang**, WK Leung, WY Lee, YP Wong, S Cheung, SL Luk, AS Lee, SY Yeung, Oliver Blanck. Target localization of 3D versus 4D cone beam computed tomography in lipiodol-guided stereotactic radiotherapy of hepatocellular carcinomas. PLoS One 2017 Apr 6;12(4):e0174929 (Impact factor: 2.806)
6. Lee AS, Zee B, Cheung FY, Kwong P, Cheng A, **Chiang CL**, Leung KC, Siu S, Lee C, Lai M, Kwok C, Chong M, J Jolivet, Tung Y. Randomized Phase II study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC). American Journal of Clinical Oncology 2016 Dec; 39 (6): 609-613 (Impact factor: 3.062)
7. Chan MK, Lee V, **Chiang CL**, Lee FA, Law G, Sin NY, Siu KL, Wong FC, Tung SY, Luk H, Blanck O. Lipiodol versus Diaphragm in 4D-CBCT-guided Stereotactic Radiotherapy of Hepatocellular Carcinoma. Strahlentherapie und Onkologie. Feb 2016, 192(2): 92-101 (Impact factor: 2.735)
8. Lee SF, **Chiang CL**, Lee AS, Wong CS. Capecitabine Associated Severe Ileitis Despite Previous Uncomplicated Treatment Courses: Two Case Reports and Review of the Literature. Molecular and Clinical Oncology 2015 Nov; 3(6): 1298-1400

#### International Journal: Proceeding Abstracts

1. **CL Chiang**, VWY Lee, CSY Yeung, MYP Wong, FAS Lee. External Beam Radiotherapy (EBRT) And High Dose Rate Brachytherapy (HDRBT) in Rectal Cancer Patients Who Are Medically Unfit Or Refuse Surgery. Radiotherapy Oncol 2017 May;123 (S1):S678-679 (Impact factor: 4.328)

2. **CL Chiang**, AS Lee, KK Choi, SY Yeung, YP Wong, WK Leung, WY Lee, KH Chan, Y Tung. Stereotactic Body Radiation Therapy (SBRT) Combined With Transarterial Chemoembolization (TACE) in BCLC Stage B and C Hepatocellular Carcinoma (HCC). *Int J Radiat Oncol Biol Phys.* 2016 Oct;96(2):Supplement: E162 (Impact factor: 5.133)
3. WY Lee, YP Wong, **CL Chiang**, KH Chan, WK Leung, ML Law, AS Lee, Y Tung, DLW Kwong. Dosimetric Comparison Between MAR and Non MAR CT Based HDR Endorectal Brachytherapy Using Shielded Intracavitary Mould Applicator. *Brachytherapy.* 2016 May-Jun; 15(S1); S33 (Impact factor: 2.082)
4. **CL Chiang**, AS Lee, Ronnie WK Leung, Venus WY Lee, KK Choi, CS Wong, WK Sze, Y Tung, Mark KH Chan. Clinical outcomes of 4D CBCT-guided stereotactic body radiotherapy for inoperable hepatocellular carcinomas. *Radiother Oncol.* 2015 Apr;115(S1):S342-343 (Impact factor: 4.328)
5. **Chiang CL**, Lee AS, Choi KK, Wong CS, Sze WK, Tung Y. Combined Trans-Arterial Chemoembolization (TACE) and Stereotactic Body Radiation Therapy (SBRT) for Inoperable HCC. *Radiother Oncol.* 2014 Apr;111(S1):S113-114 (Impact factor: 4.328)
6. **Chiang CL**, Lee AS, Choi KK, Wong CS, Sze WK, Tung Y. AFP Response as a Predictor for Clinical Outcome after Stereotactic Body Radiotherapy (SBRT) of Advanced HCC. *Radiother Oncol.* 2013 Mar;106 (S2):S17 (Impact factor: 4.328)
7. Lee AS, Wong V, **Chiang CL**, Choi C, Tung Y. Individualized hypofractionated radiation therapy (IHRT) for advanced HCC – Single Institution Experience with 98 patients. *Int J Radiat Oncol Biol Phys.* 2012 Nov; 84 (3): S333 (Impact factor: 5.133)

#### **Local Journal: Original Articles & Review Articles**

1. **CL Chiang**, CSY Yeung, MYP Wong, VWY Lee, VHF Lee, FAS Lee, FCS Wong. Emerging Role of Stereotactic Body Radiotherapy (SBRT) in the Management of Pancreatic Cancer. *Hong Kong J Radiol.* 2017;20:303-11
2. **CL Chiang**, FAS Lee, YW Wong, CM Poon, CKK Choi, FCS Wong, WK Sze, SY Tung. Pre-op short-course radiotherapy with elective delay surgery (PSCRT-delay) in locally advanced rectal cancer patients among Chinese population. *Hong Kong J Radiol* 2017;20:312-7
3. **CL Chiang**. Combined immunotherapy and radiotherapy. *Hong Kong medical diary* Volume 22(6) June 2017
4. Winnie Yeo, KO Lam, Ada LY Law, Conrad CY Lee, **CL Chiang**, KH Au, Frankie KF Mo, TH So, KC Lam, WT Ng, L Li. Adjuvant TS-1 Chemotherapy after Curative Resection of Gastric Cancer in Chinese Patients – Assessment of Treatment Tolerability and Associated Risk Factors. *Hong Kong Med J* 2017 Feb; 23(1): 54-62 (Impact factor: 1.111)

#### **Oral Presentations at Academic Conferences**

##### **International**

1. Cost-effectiveness analysis of additional Abiraterone for hormone-sensitive metastatic prostatic cancer treated with androgen deprivation therapy (ADT). *ESMO Asia (19-Nov-2017)*, Singapore
2. Short course pre-operative radiotherapy with elective delayed surgery in rectal cancer: Report on our early experience. 20<sup>th</sup> Hong Kong International Cancer Congress (12-Nov-2013), Hong Kong

##### **Local**

1. External Beam Radiotherapy followed by Brachytherapy Boost in Locally Advanced Rectal Cancer Patients who are Medically Unfit or Refuse Surgery. 24<sup>th</sup> Annual Scientific Meeting of Hong Kong College of Radiologists (12-Nov-2016), Hong Kong

2. Pre-operative Chemoradiotherapy (PCRT) for Locally Advanced Rectal cancer: Analysis of Clinical Outcome from a Single Institution Experience. 20<sup>th</sup> Annual Scientific Meeting of Hong Kong College of Radiologists (27-Oct-2012), Hong Kong

#### Abstract presentations at Academic Conferences

1. CL Chiang, VWY Lee, CSY Yeung, ZY Xu, FAS Lee, ZJ Chen. 圖像引導近距离放療 (IGBT) 在直腸癌根治性治療中的應用 — 單中心初步結果, CSTRO (9-Nov-2017), Beijing, China
2. HM Ho, **CL Chiang**, AS Lee, CH Chan, SY Yeung, KK Choi, CS Wong, Y Tung. Albumin-Bilirubin (ALBI) versus Child-Pugh (CP) Score as a predictor of survival after Stereotactic Body Radiotherapy (SBRT) in Hepatocellular Carcinoma (HCC), ASTRO's 59<sup>th</sup> Annual meeting (25-Sep-2017), San Diego, United States
3. SY Yeung, **CL Chiang**, AS Lee, HM Ho, Y Tung. 8Gy Single Fraction (8Gy/1Fr) Palliative Radiotherapy (RT) For Hepatocellular Carcinoma (HCC): Safety And Efficacy. 8<sup>th</sup> Asia-Pacific Primary Liver Cancer Expert Meeting (15-Jul-2017), Singapore
4. Lam KO, Lo AWI, Choi HCW, Ho I, Law BTT, Chan WL, Lee VHF, So TH, **Chiang CL**, Chan SY, Tong DKH, Kwong DLW, Law SYK. PD-L1 Hotspot in Tumor-infiltrating Lymphocytes of Radically Treated Esophageal Squamous Cell Carcinoma: Pattern of Recurrence and Long-term Clinical Outcome. 19<sup>th</sup> World Congress of Gastrointestinal Cancer (29-Jun-2017), Barcelona, Spain
5. MKH Chan, **CL Chiang**, RWK Leung, MYP Wong, Oliver Blanck. Modeling Clinical Outcome of Combined Transarterial Chemoembolization Stereotactic Body Radiotherapy of Hepatocellular Carcinoma using Mid-Ventilation Planning Target Volume Concept with 4D Cone Beam Computed Tomography. DEGRO (15-Jun-2017), Berlin, Germany
6. **CL Chiang**, CSY Yeung, CHM Ho, CKK Choi, AS Lee. Combined Transarterial Chemoembolization (TACE) and Stereotactic Body Radiotherapy (SBRT) In HKLC Intermediate And Locally Advanced Hepatocellular Carcinoma (HCC). 7<sup>th</sup> Asia-Pacific Primary Liver Cancer Expert Meeting (9-Jul-2016), Hong Kong
7. KK Choi, AS Lee, **CL Chiang**, FCS Wong, WK Sze, SY Tung. The Efficacy, Toxicities and Prognostic Factors of Stereotactic Radiotherapy in Locally Advanced Unresectable Hepatitis B Related Hepatocellular Carcinoma. 7<sup>th</sup> Asia-Pacific Primary Liver Cancer Expert Meeting (9-Jul-2016), Hong Kong
8. **CL Chiang**, CH Chan, SH Lo, WK Sze, Y Tung. Manage patients with malignant pleural effusion (MPE) using indwelling pleural catheter (IPC) for intermittent drainage at outpatient setting: A safe and cost effective approach. Asian Pacific Hospice Conference (1-May-2015), Taipei, China
9. **Chiang CL**, Lee AS, Choi KK, Wong CS, Sze WK, Tung Y. Clinical outcome of conversion chemotherapy plus Cetuximab in patients with RAS wild type colorectal liver metastases: A single institutional retrospective analysis. 22nd Annual Scientific Meeting of Hong Kong College of Radiologists (1-Nov-2014). Hong Kong
10. **Chiang CL**, Lee AS, Choi KK, Wong CS, Sze WK, Tung Y. Post-chemoradiotherapy (CRT) Pathological Stage (yp stage) as an Early Prognosticator of patients with Rectal Cancer. 21<sup>st</sup> Annual Scientific Meeting of Hong Kong College of Radiologists (2-Nov-2013). Hong Kong
11. **Chiang CL**, Lee AS, Choi KK, Yuen KK, Wong CS, Sze WK, Tung Y. Tolerance and Clinical Outcomes of Pre-operative Chemoradiotherapy (PCRT) for rectal cancer in elderly patients, 20<sup>th</sup> Annual Scientific Meeting of Hong Kong College of Radiologists (27-Oct-2012), Hong Kong

#### Invited Lectures and Talk

#### International Conference / Overseas Institution

1. 放射治療於肝癌的應用, 粵港澳大灣區腫瘤高峰論壇暨第十屆番禺腫瘤論壇, Panyu, China, to deliver on 6-July-2018
2. Is there still a role of Radiotherapy in Locally Advanced Pancreatic Cancer? Asia-Pacific Gastroenterology Cancer Summit – APGCS2018, Singapore (5-May-2018)
3. 直腸癌單純放療. 直腸癌放療專題學術講座, The University of Hong Kong Shenzhen Hospital (28-Jul-2017)
4. Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma (HCC): Hong Kong Experience. Radiation Oncology Department Meeting, Jewish General Hospital, Montreal, Canada (6-Aug-2015)
5. Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma (HCC): Hong Kong Experience. Liver Tumour Board Meeting, John Hopkins Hospital, Baltimore, United States (2-Oct-2013)
6. Combined Trans-Arterial Chemo-Embolization (TACE) and Stereotactic Body Radiotherapy (SBRT) for Inoperable Hepatocellular Carcinoma (HCC). Residents' Training Lecture. John Hopkins Hospital, Baltimore, United States (4-Oct-2013)

### **Local Conference / Symposium / Institution**

1. Current Perspective of SBRT in Liver and Pancreatic Cancer, to deliver in 26<sup>th</sup> Annual Scientific Meeting of Hong Kong College of Radiologists, Hong Kong (Nov-2018), Hong Kong
2. SBRT for Locally Advanced CA Pancreas, to deliver in HKSBR T Study Group First Scientific Meeting, Hong Kong (30-Jun-2018)
3. Recent Advance in Management on Pancreatic Cancer, Multi-specialty Medical Mega Conference Eighth Round, Hong Kong (22-Apr-2018)
4. Recent Advance in Radiotherapy of Rectal Cancer, Multi-specialty Medical Mega Conference Eighth Round, Hong Kong (22-Apr-2018)
5. Recent Advance in radiotherapy of rectal cancer, 25<sup>th</sup> Annual Scientific Meeting of Hong Kong College of Radiologists, Hong Kong (18-Nov-2017)
6. Clinical and Research Development on Immuno-oncology in Hong Kong, Immuno-Oncology in Bladder Cancer: What have we learned and next steps, Hong Kong (22-Sep-2017)
7. Management of metastatic colorectal cancer, Precision Oncology Symposium, Hong Kong (15-Jun-2017)
8. Brachytherapy for Rectal Cancer, Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong (29-May-2017)
9. Non-surgical management of Pancreatic Cancer. HBP Surgical Nursing Seminar, Hong Kong (26-Nov-2016)
10. Case Sharing Session on Metastatic Pancreatic Cancer, Round Table Discussion on Management of Metastatic Pancreatic Cancer, Hong Kong (27-Apr-2016)
11. Clinical Approach in Rechallenge Use of Cetuximab (During Treatment Break Progression), The 4<sup>th</sup> Oncology Summit, Hong Kong (12-Sep-2015)
12. Case sharing: Experience on using Bevacizumab in metastatic colorectal cancer patient: Safety in the Management of Colorectal Cancer, Oncologists and Surgeons Expert Forum, Hong Kong (29-Mar-2014)

### **Grant**

#### **External peer-reviewed competitive Grant**

Principal investigator

1. Health and Medical Research Fund (2017): Cost Effectiveness of Anti-EGFR Antibodies as First Line Treatment in RAS Wild Type (WT) Metastatic Colorectal Cancer (mCRC) in Hong Kong (Project no: 15161781) (HK \$99,627)
2. Li Shu Pui Medical Foundation Research Grants (2017): Clinical Validation of Genomic Guided Radiation Dose (GARD) in Nasopharyngeal Carcinoma (NPC) (HK\$1,453,000)

Co-investigator

1. Li Shu Pui Medical Foundation Research Grants (2017): Stereotactic body radiation therapy using Cyberknife (M6) radiosurgery system for locally advanced or inoperable and unresectable hepatocellular carcinoma (HK\$1,500,000)

#### **External non-peer reviewed non-competitive research grants**

Principal investigator

1. Bayer HealthCare Limited (2017): Treatment outcome of refractory metastatic colorectal cancer (HK \$ 100000)
2. Astra Zeneca Hong Kong Kong Limited (2017): Prognostic significance of radiotherapy induced change of PD-L1 expression of rectal adenocarcinoma (HK \$ 100000)

#### **Internal Grant**

Principal investigator

1. Seed Fund for Basic Research for New Staff (2017): Prospective Multi-center Single Arm Phase II Trial of External Radiotherapy plus Endorectal Brachytherapy Boost as Radical Treatment in Rectal Cancer Patients (HK \$ 150000)
2. Enhanced New Staff Start-up Research Grant (2017): Clinical Validation on Predictive Biomarkers of Radio-sensitivity in Rectal Cancer (HK \$ 380000)

#### **Other Grant**

1. URC/CRCG - Conference Support for Teaching Staff (May-2017): ESTRO conference 2017 (\$ 16500)
2. URC/CRCG – Conference Support for Teaching Staff (Sep-2017): 59<sup>th</sup> ASTRO conference 2017 (\$ 16500)

### **Journal Reviewer**

1. Oncotarget

### **Knowledge Exchange**

#### **Public Talk**

1. 癌症治療新趨勢 (21-Jun-2017), AIA Hong Kong Tower, Hong Kong
2. 認識腸癌治療新趨勢 (21-Jul-2017), Cancer Patient Information Center, Queen Mary Hospital, Hong Kong

#### **Media**

1. MIMS Oncology Interview: Role of anti-EGFR therapy in right sided RAS wild type mCRC (15-Sep-2017)
2. 明報《癌治準繩》：零距滅直腸癌 新電療快狠準 毋須手術 解救老年患者 (18-Sep-17)
3. 明報《癌治準繩》：改良電療瞄準肝癌 射死腫瘤 紓緩末期苦 (30-Oct-17)
4. 明報《癌治準繩》：狙擊超級殺手胰臟癌 中期有望痊癒 不再等死 (25-Dec-17)
5. 有線電視《至Fit男女》專訪：追擊胰臟癌 (17-Mar-18)
6. 明報《癌治準繩》：新電療隔山打牛 激活免疫系統抗癌 (2-Apr-18)
7. 有線電視《至Fit男女》專訪：肝癌新治療 (12-May-18)
8. 明報《癌治準繩》：膽管癌：罕見的致命殺手 (25-Jun-18)

### **Education**

#### **Training of Clinicians**

1. Colon, Rectum, Anus (I)(II). FRCR Part II examination training lecture (2017 - present)
2. Palliative Care (II): Oncological Emergencies and Symptom Management. FRCR Part II examination lecture (2016)
3. Sharing of Successful Experience of Part II Examination. FRCR Part II examination lecture (2012)

#### **Supervision of Research Post-graduate Students**

1. Master of Medical Science: 1 student

#### **Undergraduate Education**

1. Invigilator, MBBS Fourth Summative Examination (10-May-2018)
2. Examiner, MBBS Second Summative OSCA examination (23-May-2017, 30-May-2018)
3. Interviewer of Multi-Mini Interviews (MMI), MBBS non-JUPAS and JUPAS applicants (Nov-2017, Jun-2018)
4. Clinical Academic Advisor of MBBS 3-5 students, LKS Faculty of Medicine (2017 - present)
5. MBBS Year 3 Junior Clerkship Block Deputy Coordinator (2017- present)
6. Tutor of Health Research Project for MBBS Year 1 (2017- present)
7. Teaching Clinic on 'Top Cancers in Hong Kong II' for MBBS Year 3 (2017- present)
8. Whole Class Session on 'Advances in Systemic Therapy' for MBBS Year 5 (2017- present)

### **Leading Role in Local/International Professional Organizations**

1. Hong Kong Stereotactic Body Radiotherapy Society (Limited): Treasurer and Council member (2017-present)
2. Pan-Pearl River Area Radiation Therapy Oncology Group (PPRA-RTOG) 泛珠江区域肿瘤放射治疗协作组 執行委員 (2018-present)

### **University and Hospital Administrative Service**

1. Equal Opportunity Advisor, Department of Clinical Oncology, LKS Faculty of Medicine (2017 to present)
2. 副組長, 住院醫師規範培訓基地, Clinical Oncology Center, HKU-SZH (2017 to present)
3. Core member, 三级综合医院甲等评审, Clinical Oncology Center, HKU-SZH (2017)

4. Core member, Sanming Project of Medicine in collaboration of Department of Radiation Oncology, Princess Margaret Hospital (Toronto), Clinical Oncology Center, HKU-SZH (2017-present)
5. Committee Member (Oncology Service), Grantham Hospital Redevelopment Senior Management Planning Workshop (2017-present)

#### **Clinical Service Innovation**

1. Setup hepato-biliary-pancreatic (HBP) cancer multi-disciplinary tumor (MDT) board in HKU-SZH (2018)
2. Setup rectal brachytherapy service in Queen Mary Hospital (2018)

#### **Organizer of Conferences**

1. Organizer, 3<sup>rd</sup> Hong Kong Shenzhen International Cancer Congress (14-May-2017)
2. Organizer, Sanming Project of Medicine -The 2nd International Symposium on Specialist Education and Advances in Radiation Oncology (2-Dec-2017)
3. Organizer, Hong Kong Stereotactic Body Radiotherapy Study Group Inaugural Symposium and First Scientific Meeting (30-Jun-2018)
4. Organizing Committee, Hong Kong International Oncology Forum and 4<sup>th</sup> Hong Kong-Shenzhen International Cancer Congress (7-9 Sep-2018)
5. Organizer, Sanming Project of Medicine -The 3rd International Symposium on Specialist Education and Advances in Radiation Oncology (2-Dec-2018)

#### **Clinical Trial Experiences**

##### **As principal investigators or co-investigators of more than 20 clinical trials**

1. Co-investigator, Protocol A6181087 (Pfizer): A multi-center randomized, double-blind, controlled phase III, efficacy and safety study of Sunitinib (SU011248) in patients with Advanced/Metastatic Non-Small Cell Lung Cancer treated with Erlotinib (2008)
2. Co-investigator, Protocol A6181087 (Pfizer): A multi-center randomized, double-blind, controlled phase III, efficacy and safety study of Sunitinib (SU011248) in patients with Advanced/Metastatic Non-Small Cell Lung Cancer treated with Erlotinib (2008)
3. Co-investigator, Protocol 20050201: A Phase 3, Multicenter, randomized, placebo -controlled, double-blinded trial of AMG706 in combination with Paclitaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer (2008)
4. Co-investigator, Protocol CRAD001J2301: A randomized phase III, double-blind, placebo-controlled multicenter trial of Everolimus in combination with Trastuzumab and Paclitaxel, as first line therapy in women with HER2 Positive Locally Advanced or Metastatic Breast Cancer (2009)
5. Co-investigator, Protocol AEG35156-205: A Phase 1-2, Open Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination with Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) (2009)
6. Co-investigator, Protocol CRAD001Y2301: A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer who are refractory to Letrozole or Anastrozole (2009)
7. Co-investigator, Protocol 3144A2-3004-WW: A Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women with Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer (2009)
8. Co-investigator, Protocol 20080763: A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects with Previously Treated, Wild -type KRAS, Metastatic Colorectal Cancer (2009)
9. Co-investigator, Protocol EMR200048-052: (Erbix in combination with Xeloda and cisplatin in advanced esophago-gastric cancer) - Open-label, randomized, controlled, multicenter phase III study investigating cetuximab in combination with capecitabine (Xeloda, X) and cisplatin (P) versus XP alone as first-line treatment for subjects with advanced Gastric Adenocarcinoma including adenocarcinoma of the gastroesophageal junction (2009)
10. Co-investigator, Protocol EGF110656: A Phase III Study of ErbB2 Positive advanced or Metastatic Gastric or Esophageal or Gastroesophageal Junction Adenocarcinoma Treated with Capectiabine plus Oxaliplatin with or without Lapatinib (2010)
11. Co-investigator, Protocol MORAb-003-004: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-sensitive Ovarian Cancer in First Relapse (2010)
12. Co-investigator, Protocol CA 182-037: A Randomized, Double-blind, Multicenter Phase III Study of Brivanib versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients with Unresectable Hepatocellular Carcinoma: The BRISK TA Study (2010)

13. Co-investigator, Protocol 3.1: A double-blind, randomized, parallel group, Phase III study to demonstrate equivalent efficacy and comparable safety of CTP6 and Herceptin, both in combination with paclitaxel, in patients with Metastatic Breast Cancer (2011)
14. Co-investigator, Protocol IMCL CP12-0922: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC -1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine (2011)
15. Co-investigator, Protocol 0060540: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination with Gemcitabine as First-line Therapy for Metastatic Adenocarcinoma of the Pancreas (2011)
16. Co-investigator, Protocol A8081014 (Pfizer): Phase 3, Randomized, open-label study of the efficacy and safety of Crizotinib versus Pemetrexed/Cisplatin or Pemetrexed/Carboplatin in previously untreated patients with Non- Squamous Carcinoma of the Lung harboring a Translocation in Inversion event involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus (2012)
17. Co-investigator, Met Gastric (Roche) YO28322: A Randomised, Phase III, Multicenter, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Onartuzumab (MetMab) in Combination with 5-Fluorouracil, Folinic Acid, and Oxaliplatin (mFOLFOX6) in Patients with Metastatic HER2-negative, Met- Positive Gastroesophageal Cancer (2013)
18. Co-investigator, GO 28341 (PPD): A Phase II Study of GDC-0068 in combination with Fluoropyrimidine plus Oxaliplatin versus Fluoropyrimidine Plus Oxlipatin in Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal junction Adenocarcinoma (2013)
19. Co-investigator, E7080-G000-304 (Quintiles): A Multicenter, randomized, open-label, phase 3 trial to compare the efficacy and safety of Lenvatinib (E7080) Versus Sorafenib in first-line treatment of subjects with Unresectable Hepatocellular Carcinoma (2013)
20. Co-investigator, HKU-SEG-Y001 (HKU): Randomised Phase II Trial of Sorafenib, Capecitabine and Oxaliplatin (SECOX) versus Single Agent Sorafenib in Patients with Advanced Hepatocellular Carcinoma (2013)
21. Co-investigator, AB12006: A prospective, multicenter, randomized, double blind, placebo -controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5 - fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients with metastatic colorectal cancer (2014)
22. Co-investigator, ABI-007-PANC-003: A Phase 3, Multicenter, Open-label, Randomized Study of nab®-Paclitaxel Plus Gemcitabine versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma (2014)
23. Co-investigator, 4T-MC-JVDE: Randomized, double-blind, placebo-controlled, phase 3 study of Ramucirumab and Best Supportive Care (BSC) versus placebo and BSC as second-line treatment in patient with Hepatocellular Carcinoma and elevated baseline Alph-Fetoprotein (AFP) following first-line therapy with Sorafenib (2015)
24. Co-investigator, 9785-CL-3021: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects with Advanced Hepatocellular Carcinoma Protocol for Phase 2 Study of Enzalutamide (2015)
25. Co-Investigator, MK3475-181: A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First -Line Standard Therapy (2016)